Seres Therapeutics Inc. Common Stock (MCRB)
Stock · NASDAQ · Health Care
$2.46as of 10/16/2026
Price chart
Active signals
MCRB Signal Track Record
How signals performed across all stocks →What MCRB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -10.8% | 35% | October 8, 2026 |
| Bollinger Band Breakdown | 23 | +0.5% | 52% | June 3, 2026 |
| Bollinger Band Breakout | 23 | -9.4% | 26% | September 2, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -0.8% | 47% | February 9, 2026 |
| Any 20-session window (baseline) | -4.8% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MCRB
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allo…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 66
- Website
- www.serestherapeutics.com/
Fundamentals
- 1-day range
- $2.42$2.72
- Market cap
- $48.42M
- P/E (trailing)
- —
- P/E (forward)
- -0.53
- EPS (trailing)
- $-2.33
- Dividend yield
- —
- Beta
- 0.48
- Avg. volume
- 72.0K
How Seres Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Seres Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MCRBSeres Therapeutics Inc. Common Stock$2.46▼ 2.77%Market cap $48.42MP/E —$2.8$29.98
- TCRTAlaunos Therapeutics Inc. Common Stock$2.63▲ 20.64%Market cap $48.60MP/E —$0.719$4.5
- IBOImpact BioMedical Inc. Common Stock$2.68▼ 15.14%Market cap $48.61MP/E 61.61$4.67$10.47
- MREOMereo BioPharma Group plc American Depositary Shares$0.303▼ 1.94%Market cap $47.46MP/E —$0.2$2.37
- FLNAFilana Therapeutics Inc. Common Stock$0.7▼ 7.89%Market cap $46.33MP/E —$0.6701$2.27
- CNTXContext Therapeutics Inc. Common Stock$0.244▲ 1.24%Market cap $46.31MP/E —$0.2358$3.62
- SCYXSCYNEXIS Inc. Common Stock$3.67▼ 6.14%Market cap $51.64MP/E —$3.53$9.12
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MCRB Seres Therapeutics Inc. Common Stock | $48.42M | — | $2.46 | ▼ 2.77% | $2.8$29.98 |
| TCRT Alaunos Therapeutics Inc. Common Stock | $48.60M | — | $2.63 | ▲ 20.64% | $0.719$4.5 |
| IBO Impact BioMedical Inc. Common Stock | $48.61M | 61.61 | $2.68 | ▼ 15.14% | $4.67$10.47 |
| MREO Mereo BioPharma Group plc American Depositary Shares | $47.46M | — | $0.303 | ▼ 1.94% | $0.2$2.37 |
| FLNA Filana Therapeutics Inc. Common Stock | $46.33M | — | $0.7 | ▼ 7.89% | $0.6701$2.27 |
| CNTX Context Therapeutics Inc. Common Stock | $46.31M | — | $0.244 | ▲ 1.24% | $0.2358$3.62 |
| SCYX SCYNEXIS Inc. Common Stock | $51.64M | — | $3.67 | ▼ 6.14% | $3.53$9.12 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Rosiello Robert L. · July 8, 2026 · Grant6.5K
- Berenson Stephen · July 8, 2026 · Grant6.5K
- Henn Matthew R · July 8, 2026 · Grant25.0K
- Thorell Marella · July 8, 2026 · Grant7.5K
- Shaff Eric D. · July 8, 2026 · Grant6.5K
- Brady Kelly · July 8, 2026 · Grant18.8K
- DesRosier Thomas · July 8, 2026 · Grant7.5K
- Graves Kurt · July 8, 2026 · Grant6.5K
- Claire Fraser · July 8, 2026 · Grant6.5K
- Ausiello Dennis A · July 8, 2026 · Grant6.5K
- Kender Richard N · July 8, 2026 · Grant50.0K
- Willard H. Dere · July 8, 2026 · Grant6.5K
- Berenson Stephen · July 1, 2026 · Grant7.5K
- Rosiello Robert L. · July 1, 2026 · Grant7.5K
- Ausiello Dennis A · July 1, 2026 · Grant7.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 2.45M
- Total value held
- $21.70M
- Institutional holders
- 32
- Unknown1.16M
- Unknown294.1K
- Unknown226.9K
- Unknown139.5K
- Unknown138.5K
- Unknown102.0K
- Unknown74.8K
- Unknown62.3K
- Unknown59.5K
- Unknown33.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026
Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026. Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.